drugset / Trial / NCT03511326

PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK

NCT03511326

Phase 4 Completed 50 enrolled Galderma R&D
NaSingle-groupOpen-labelOther

Summary

Interventional open label prospective and multicentre study conducted in Germany in subjects with thin or non-hyperkeratotic and non-pigmented multiple AKs in one anatomical area on the face (e.g., forehead or cheek or chin), excluding nose eyelids, lips and mucosa or balding scalp, using Luxerm® DL-PDT treatment.

Timeline

Start
2017-06-07
Primary completion
2017-11-28
Completion
2017-11-28

Drugs

EvaluationDrugModalityDoseRoute
Subject methyl aminolevulinate Small molecule 16 %

Indications